With over 500 individual compounds, the Amaryllidaceae alkaloids represent a large and structurally diverse group of phytochemicals. Coupled to this structural diversity is the significant array of biological properties manifested by many of its members, of which their relevance in motor neuron disease and cancer chemotherapy has attracted considerable attention. To this extent, galanthamine has evolved into a successful commercial drug for Alzheimer's disease since its approval by the FDA in 2001. Concurrently, there have been several positive indicators for the emergence of an anticancer drug from the Amaryllidaceae due to the potency of several of its representatives as cell line specific antiproliferative agents. In this regard, the phenanthridones such as pancratistatin and narciclasine have offered most promise since their advancement into clinical trials, following which there has been renewed interest in the cytotoxic properties of these alkaloids. Given this background, this review seeks to highlight the various mechanisms which have been invoked to corroborate the cytotoxic effects of Amaryllidaceae alkaloids.
DahlgrenRMT, CliffordHT. (1982) The Monocotyledons: a Comparative Study. Academic Press, London, 1–378
2.
MeerowAW, SnijmanDA. (1998) Amaryllidaceae. In The Families and Genera of Vascular Plants. Vol. 3, KubitzkiK. (Ed). Springer, Berlin, Germany, 83–110.
3.
Caamal-FuentesE, Torres-TapiaLW, Simá-PolancoP, Peraza-SánchezSR, Moo-PucR. (2011) Screening of plants used in Mayan traditional medicine to treat cancer-like symptoms. Journal of Ethnopharmacology, 135, 719–724
4.
BastidaJ, LavillaR, ViladomatF. (2006) Chemical and biological aspects of Narcissus alkaloids. In The Alkaloids. CordellGA. (Ed). Elsevier, Amsterdam, Netherlands, 87–179
5.
NairJJ, Van StadenJ. (2013) Pharmacological and toxicological insights to the South African Amaryllidaceae. Food and Chemical Toxicology, 62, 262–275
6.
HartwellJL. (1967) Plants used against cancer. A survey. Lloydia, 30, 379–437.
7.
HarveyAL. (1995) The pharmacology of galanthamine and its analogues. Pharmacolgy & Therapeutics, 68, 113–128
8.
HeinrichM, TeohHL. (2004) Galanthamine from snowdrop- the development of a modern drug against Alzheimer's disease from local Caucasian knowledge. Journal of Ethnopharmacology, 92, 147–162
9.
HoughtonPJ, RenY, HowesM-J. (2006) Acetylcholinesterase inhibitors from plants and fungi. Natural Product Reports, 23, 181–199.
10.
ViladomatF, BastidaJ, CodinaC, NairJJ, CampbellWE. (1997) Alkaloids of the South African Amaryllidaceae. In Recent Research Developments in Phytochemistry, Vol. 1, PandaliSG. (Ed). Research Signpost Publishers, Trivandrum, India, 131– 171
11.
NairJJ, BastidaJ, CodinaC, ViladomatF, Van StadenJ. (2013) Alkaloids of the South African Amaryllidaceae: a review. Natural Product Communications, 8, 1335–1550
KornienkoA, EvidenteA. (2008) Chemistry, biology and medicinal potential of narciclasine and its congeners. Chemical Reviews, 108, 1982–2014
14.
NairJJ, BastidaJ, ViladomatF, Van StadenJ. (2012) Cytotoxic agents of the crinane series of Amaryllidaceae alkaloids. Natural Product Communications, 7, 1677–1688
15.
NairJJ, Van StadenJ. (2014) Cytotoxicity studies of lycorine alkaloids of the Amaryllidaceae. Natural Product Communications, 9, 1193–1210.
16.
CookJW, LoudonJD. (1952) Alkaloids of the Amaryllidaceae. In The Alkaloids. Vol. 2, ManskeRHF, HolmesHL. (Eds). Academic Press, New York, USA, 331–352
17.
NakagawaY, UyeoS, YayimaH. (1956) The double bond in lycorine. Chemistry & Industry, 1238–1239
YamaguchiK, SudaS. (1952) The changes in spermatocytes of Vicia faba treated with lycorine or lycorenine. Folia Pharmacologica Japonica, 48, 31–32
20.
De LeoP, DalessandroG, De SantisA, ArrigoniO. (1973) Inhibitory effect of lycorine on cell division and cell elongation. Plant and Cell Physiology, 14, 481–486
21.
De LeoP, DalessandroG, De SantisA, ArrigoniO. (1973) Metabolic responses to lycorine in plants. Plant and Cell Physiology, 14, 487–496
22.
CeriottiG. (1967) Narciclasine: an antimitotic substance from Narcisssus bulbs. Nature, 213, 595–596
23.
ArrigoniO, ArrigoniLR, CalabreseG. (1975) Lycorine as an inhibitor of ascorbic acid biosynthesis. Nature, 256, 513–514
24.
LisoR, CalabreseG, BitontiMB, ArrigoniO. (1984) Relationship between ascorbic acid and cell division. Experimental Cell Research, 150, 314–320
25.
LuH, WanQ, WangH, NaX, WangX, BiY. (2012) Oxidative stress and mitochondrial dysfunctions are early events in narciclasine-induced programmed cell death in tobacco Bright Yellow-2 cells. Physiologia Plantarum, 144, 48–58.
26.
CarrascoL, FresnoM, VazquezD. (1975) Narciclasine: an antitumour alkaloid which blocks peptide bond formation by eukaryotic ribosomes. FEBS Letters, 52, 236–239
27.
JimenezA, SanchezL, VazquezD. (1975) Location of resistance to the alkaloid narciclasine in the 60S ribosomal subunit. FEBS Letters, 55, 53–56
28.
JimenezA, SanchezL, VazquezD. (1975) Yeast ribosomal sensitivity and resistance to the Amaryllidaceae alkaloids. FEBS Letters, 60, 66–70
29.
BaezA, VazquezD. (1978) Binding of [3H]narciclasine to eukaryotic ribosomes. A study on a structure-activity relationship. Biochimica et Biophysica Acta, 518, 95–103
30.
KukhanovaM, VictorovaL, KrayevskyA. (1983) Peptidyltransferase center of ribosomes. On the mechanism of action of alkaloid lycorine. FEBS letters, 160, 129–133
31.
JimenezA, SantosA, AlonsoG, VazquezD. (1976) Inhibitors of protein synthesis in eukaryotic cells. Comparative effects of some Amaryllidaceae alkaloids. Biochimica et Biophysica Acta, 425, 342–348
32.
VrijsenR, Vanden BergheDA, VlietinckAJ, BoeyéA. (1986) Lycorine: a eukaryotic termination inhibitor. The Journal of Biological Chemistry, 261, 505–507
33.
LiuJ, YangY, XuY, MaC, QinC, ZhangL. (2011) Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication. Virology Journal, 8, 483–491
Rodriquez-FonsecaC, AmilsR, GarrettRA. (1995) Fine structure of the peptidyltransferase centre on 23S-like rRNAs deduced from chemical probing of antibiotic-ribosome complexes. Journal of Molecular Biology, 247, 224–235.
36.
FurusawaE, FurusawaS, MorimotoS, CuttingW. (1971) Therapeutic activity of Narcissus alkaloid on Rauscher leukemia and comparison with standard drugs. Proceedings of the Society for Experimental Biology and Medicine, 136, 1168–1173
37.
FurusawaE, SuzukiN, RamanathanS, FurusawaS, CuttingW. (1972) Effect of long-term administration of Narcissus alkaloid on Rauscher leukemia and combinations with standard drugs. Proceedings of the Society for Experimental Biology and Medicine, 140, 1034–1040
38.
PapasTS, SandhausL, ChirigosMA, FurusawaE. (1973) Inhibition of DNA polymerase of avian myeloblastosis virus by an alkaloid extract from Narcissus tazetta L. Biochemical and Biophysical Research Communications, 52, 88–92.
39.
ChattopadhyayS, ChattopadhyayU, MathurPP, SainiKS, GhosalS. (1983) Effects of hippadine, an Amaryllidaceae alkaloid, on testicular function in rats. Planta Medica, 49, 252–254
40.
Abd El HafizMA, RamadanMA, JungML, BeckJP, AntonR. (1991) Cytotoxic activity of Amaryllidaceae alkaloids from Crinum augustum and Crinum bulbispermum. Planta Medica, 57, 437–439
41.
Schmeda-HirschmannG, AstudilloL, BastidaJ, ViladomatF, CodinaC. (2000) DNA binding activity of Amaryllidaceae alkaloids. Boletín de la Sociedad Chilena de Quimica, 45, 515–518
42.
Abou-DoniaAH, AmerME, DarwishFA, KassemFF, MammodaHM, Abdel-KaderMS, ZhouB-N, KingstonDGI. (2002) Two new alkaloids of the crinane series from Pancratium sickenbergeri. Planta Medica, 68, 379–381
43.
HohmannJ, ForgoP, MolnárJ, WolfardK, MolnárA, ThalhammerT, MathéI, SharplesD. (2002) Antiproliferative Amaryllidaceae alkaloids isolated from the bulbs of Sprekelia formosissima and Hymenocallis x festalis. Planta Medica, 68, 454–457
44.
KaradenizH, GulmezB, SahinciF, ErdemA, KayaGI, UnverN, KivcakB, OzsozM. (2003) Disposable electrochemical biosensor for the detection of the interaction between DNA and lycorine based on guanine and adenine signals. Journal of Pharmaceutical and Biomedical Analysis, 33, 295–302.
45.
PadeV, StavchanskyS. (1998) Link between drug absorption, solubility and permeability measurements in Caco-2 cells. Journal of Pharmaceutical Sciences, 87, 1604–1607
46.
BeijnenJH, FloraKP, HalbertGW, HenrarREC, SlackJA. (1995) CRC/EORTC/NCI joint formulation working party: experiences in the formulation of investigational cytotoxic drugs. British Journal of Cancer, 72, 210–218
47.
PettitGR, FreemanS, SimpsonMJ, ThompsonMA, BoydMR, WilliamsMD, PettitGRIII, DoubekDL. (1995) Antineoplastic agents 320: synthesis of a practical pancratistatin prodrug. Anti-Cancer Drug Design, 10, 243–250
48.
ShnyderSD, CooperPA, MillingtonNJ, GillJH, BibbyMC. (2008) Sodium pancratistatin 3,4-O-cyclic phosphate, a water-soluble synthetic derivative of pancratistatin, is highly effective in human colon tumor model. Journal of Natural Products, 71, 321–324
GhosalS, SainiKS, RazdanS. (1985) Crinum alkaloids: their chemistry and biology. Phytochemistry, 24, 2141–2156
51.
DasariR, BanulsLMY, MasiM, PellySC, MathieuV, GreenIR, Van OtterloWAL, EvidenteA, KissR, KornienkoA. (2014) C1,C2-ether derivatives of the Amaryllidaceae alkaloid lycorine: retention of activity of highly lipophilic analogues against cancer cells. Bioorganic & Medicinal Chemistry, 24, 923–927
52.
WangP, YuanH-H, ZhangX, LiY-P, ShangL-Q, YinZ. (2014) Novel lycorine derivatives as anticancer agents: synthesis and in vitro biological evaluation. Molecules, 19, 2469–2480
53.
SharomFJ. (2011) The P-glycoprotein multidrug transporter. Essays in Biochemistry, 50, 161–178
54.
ErikssonAH, RønstedN, GülerS, JägerAK, SendraJR, BrodinB. (2012) In vitro evaluation of the P-glycoprotein interactions of a series of potentially CNS-active Amaryllidaceae alkaloids. Journal of Pharmacy and Pharmacology, 64, 1667–1677
55.
DeekenJF, RobeyRW, ShuklaS, SteadmanK, ChakrabortyAR, PoonkuzhaliB, ShuetzEG, HolbeckS, AmbudkarSV, BatesSE. (2009) Identification of compounds that correlate with ABCG2 transporter function in the National Cancer Institute anticancer drug screen. Molecular Pharmacology, 76, 946–956.
56.
ChampouxJJ. (2001) DNA topoisomerases: structure, function and mechanism. Annual Review of Biochemistry, 70, 369–413
57.
AncuceanuRV, IstudorV. (2004) Pharmacologically active natural compounds for lung cancer. Alternative Medicine Review, 9, 402–419
58.
BarthelmesHU, NiederbergerE, RothT, SchulteK, TangWC, BoegeF, FiebigH-H, EisenbrandG, MarkoD. (2001) Lycobetaine as a selective topoisomerase IIβ poison and inhibits the growth of human tumour cells. British Journal of Cancer, 85, 1585–1591
59.
CasuL, CottigliaF, LeontiM, De LoguA, AgusE, Tse-DinhY-C, LombardoV, SissiC. (2011) Ungeremine effectively targets mammalian as well as bacterial type I and type II topoisomerases. Bioorganic & Medicinal Chemistry Letters, 21, 7041–7044
NiñoJ, HincapiéGM, CorreaYM, MosqueraOM. (2007) Alkaloids of Crinum x powellii “Album” (Amaryllidaceae) and their topoisomerase inhibitory activity. Zeitschrift für Naturforschung, 62c, 223–226
62.
SarkayaBB, ZencirS, SomerNU, KayaGI, OnurMA, BastidaJ, BerenyiA, ZupkoI, TopcuZ. (2012) The effects of arolycoricidine and narciprimine on tumor cell killing and topoisomerase activity. Records of Natural Products, 6, 381–385.
63.
YuiS, NakataniY, MikamiM. (2003) Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biological and Pharmaceutical Bulletin, 26, 753–760
64.
YuiS, MikamiM, KitaharaM, YamazakiM. (1998) The inhibitory effect of lycorine on tumor cell apoptosis induced by polymorphonuclear leukocyte-derived calprotectin. Immunopharmacology, 40, 151–162
65.
MikamiM, KitaharaM, KitanoM, ArikiY, MimakiY, SashidaY, YamazakiM, YuiS. (1999) Suppressive activity of lycoricidinol (narciclasine) against cytotoxicity of neutrophil-derived calprotectin and its suppressive effect on rat adjuvant arthritis model. Biological and Pharmaceutical Bulletin, 22, 674–678.
66.
XuW, LiuLZ, LoizidouM, AhmedM, CharlesIG. (2002) The role of nitric oxide in cancer. Cell Research, 12, 311–320
67.
Abdel-HalimOB, MorikawaT, AndoS, MatsudaH, YoshikawaM. (2004) New crinine-type alkaloids with inhibitory effect on induction of inducible nitric oxide synthase from Crinum yemense. Journal of Natural Products, 67, 1119–1124
68.
KangJ, ZhangY, CaoX, FanJ, LiG, WangQ, DiaoY, ZhaoZ, LuoL, YinZ. (2012) Lycorine inhibits lipopolysaccharide-induced iNOS and COX-2 up-regulation in RAW264.7 cells through suppressing P38 and STATs activation and increases the survival rate of mice after LPS challenge. International Immunopharmacology, 12, 249–256
69.
YamazakiY, KawanoY. (2011) Inhibitory effects of herbal alkaloids on the tumor necrosis factor-α and nitric oxide production in lipopolysaccharide-stimulated RAW264 macrophages. Chemical and Pharmaceutical Bulletin, 59, 388–391
70.
WangGL, JiangB-H, RueEA, SemenzaGL. (1995) Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proceedings of the National Academy of Sciences of the USA, 92, 5510–5514
71.
SemenzaGL. (2003) Targeting HIF-1 for cancer therapy. Nature Reviews Cancer, 3, 721–732
72.
KimYH, ParkEJ, ParkMH, BadarchU, WoldemichaelGM, BeutlerJA. (2006) Crinamine from Crinum asiaticum var. japonicum inhibits hypoxia inducible factor-1 activity but not activity of hypoxia inducible factor-2. Biological and Pharmaceutical Bulletin, 29, 2140–2142.
73.
HanahanD, WeinbergRA. (2000) The hallmarks of cancer. Cell, 100, 57–70
74.
PaulAT, GohilVM, BhutaniKK. (2006) Modulating TNF-α signaling with natural products. Drug Discovery Today, 11, 725–732.
75.
WyllieAH, KerrJF, CurrieAR. (1980) Cell death: the significance of apoptosis. International Review of Cytology, 68, 251–306
76.
ButtAJ, FirthSM, BaxterRC. (1999) The IGF axis and programmed cell death. Immunology and Cell Biology, 77, 256–262
77.
AshkenaziA, DixitVM. (1999) Apoptosis control by death and decoy receptors. Current Opinion in Cell Biology, 11, 255–260
78.
GreenDR, ReedJC. (1998) Mitochondria and apoptosis. Science, 281, 1309–1312
IngrassiaL, LefrancF, MathieuV, DarroF, KissR. (2008) Amaryllidaceae isocarbostyril alkaloids and their derivatives as promising antitumor agents. Translational Oncology, 1, 1–13
84.
EvidenteA, KornienkoA. (2009) Anticancer evaluation of structurally diverse Amaryllidaceae alkaloids and their synthetic derivatives. Phytochemistry Reviews, 8, 449–459
85.
McLachlanA, KekreN, McNultyJ, PandeyS. (2005) Pancratistatin: a natural anti-cancer compound that targets mitochondria specifically in cancer cells to induce mitosis. Apoptosis, 10, 619–630
86.
KekreN, GriffinC, McNultyJ, PandeyS. (2005) Pancratistatin causes early activation of caspase-3 and the flipping of phosphatidyl serine followed by rapid apoptosis specifically in human lymphoma cells. Cancer Chemotherapy and Pharmacology, 56, 29–38
87.
MutsugaM, KojimaK, YamashitaM, OhnoT, OgiharaY, InoueM. (2002) Inhibition of cell cycle progression through specific phase by pancratistatin derivatives. Biological and Pharmaceutical Bulletin, 25, 223–228
88.
DumontP, IngrassiaL, RouzeauS, RibaucourF, ThomasS, RolandI, DarroF, LefrancF, KissR. (2007) The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia, 9, 766–776
89.
LefrancF, SauvageS, Van GoietsenovenG, MégalizziV, Lamoral-TheysD, DebeirO, Spiegl-KreineckerS, BergerW, MathieuV, DecaesteckerC, KissR. (2009) Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells. Molecular Cancer Therapeutics, 8, 1739–1750
90.
Van GoietsenovenG, MathieuV, LefrancF, KornienkoA, EvidenteA, KissR. (2013) Narciclasine as well as other Amaryllidaceae isocarbostyrils are promising GTP-ase targeting agents against brain cancers. Medicinal Research Reviews, 33, 439–455
91.
Van GoietsenovenG, HuttonJ, BeckerJ-P, LallemandB, RobertF, LefrancF, PirkerC, VandenbusscheG, Van AntwerpenP, EvidenteA, BergerW, PrévostM, PelletierJ, KissR, KinzyTG, KornienkoA, MathieuV. (2010) Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB Journal, 24, 4575–4584
92.
JitsunoM, YokosukaA, HashimotoK, AmanoO, SakagamiH, MimakiY. (2011) Chemical constituents of Lycoris albiflora and their cytotoxic activities. Natural Product Communications, 6, 187–192
93.
NairJJ, RárováL, StrnadM, BastidaJ, Van StadenJ. (2012) Apoptosis-inducing effects of distichamine and narciprimine, rare alkaloids of the plant family Amaryllidaceae. Bioorganic and Medicinal Chemistry Letters, 22, 6195–6199
94.
PettitGR, MelodyN, HeraldDL. (2001) Antineoplastic agents. 450. Synthesis of (+)-pancratistatin from (+)-narciclasine as relay. Journal of Natural Products, 66, 2583–2587.
95.
EvidenteA, KireevAS, JenkinsAR, RomeroAE, SteelantWFA, Van SlambrouckS, KornienkoA. (2009) Biological evaluation of structurally diverse Amaryllidaceae alkaloids and their synthetic derivatives: discovery of novel leads for anticancer drug design. Planta Medica, 75, 501–507
96.
Lamoral-TheysD, DecaesteckerC, MathieuV, DuboisJ, KornienkoA, KissR, EvidenteA, PottierL. (2010) Lycorine and its derivatives for anticancer drug design. Mini-Reviews in Medicinal Chemistry, 10, 41–50
97.
ZupkóI, RétheyB, HohmannJ, MolnárJ, OcsovskiI, FalkayG. (2009) Antitumor activity of alkaloids derived from Amaryllidaceae species. In Vivo, 23, 41–48
98.
LiS, ChenC, ZhangH, GuoH, WangH, WangL, ZhangX, HuaS, YuJ, XiaoP, LiY, LiuJ, TangL, ShiY, RenW, HuW. (2007) Apoptosis induced by lycorine in KM3 cells is associated with the G0/G1 cell cycle arrest. Oncology Reports, 17, 377–384
99.
LiL, DaiH-J, YeM, WangS-L, XiaoX-J, ZhengJ, ChenH-Y, LuoY-H, LiuJ. (2012) Lycorine induces cell-cycle arrest in the G0/G1 phase in K562 cells via HDAC inhibition. Cancer Cell International, 12, 49–54
100.
HahnenE, HaukeJ, TränkleC, EyüpogluIY, WirthB, BlümckeI. (2008) Histone deacetylase inhibitors: possible implications for neurodegenerative disorders. Expert Opinion on Investigational Drugs, 17, 169–184
101.
MonneretC. (2007) Histone deacetylase inhibitors for epigenetic therapy of cancer. Anti-Cancer Drugs, 18, 363–370
102.
McNultyJ, NairJJ, BastidaJ, PandeyS, GriffinC. (2009) Structure-activity studies on the lycorine pharmacophore: a potent inducer of apoptosis in human leukemia cells. Phytochemistry, 70, 913–919
103.
LiuX-S, JiangJ, JiaoX-Y, WuY-E, LinJ-H, CaiY-M. (2009) Lycorine induces apoptosis and down-regulation of Mcl-1 in human leukemia cells. Cancer Letters, 274, 16–24
104.
Lamoral-TheysD, AndolfiA, Van GoietsenovenG, CimminoA, Le CalvéB, WauthozN, MégalizziV, GrasT, BruyèreC, DuboisJ, MathieuV, KornienkoA, KissR, EvidenteA. (2009) Lycorine, the main phenanthridine Amaryllidaceae alkaloid, exhibits significant antitumor activity in cancer cells that display resistance to proapoptotic stimuli: an investigation of structure-activity relationship and mechanistic insight. Journal of Medicinal Chemistry, 52, 6244–6256
105.
EvdokimovNM, Lamoral-TheysD, MathieuV, AndolfiA, FrolovaLV, PellySC, Van OtterloWAL, MagedovIV, KissR, EvidenteA, KornienkoA. (2011) In search of a cytostatic agent derived from the alkaloid lycorine: synthesis and growth inhibitory properties of lycorine derivatives. Bioorganic & Medicinal Chemistry, 19, 7252–7261
106.
LiuJ, HuJ-L, ShiB-W, HeY, HuW-X. (2010) Up-regulation of p21 and TNF-α is mediated in lycorine-induced death of HL-60 cells. Cancer Cell International, 10, 25–33
107.
CaoZ, YuD, FuS, ZhangG, PanY, BaoM, TuJ, ShangB, GuoP, YangP, ZhouQ. (2013) Lycorine hydrochloride selectively inhibits human ovarian cancer cell proliferation and tumor neovascularization with very low toxicity. Toxicology Letters, 218, 174–185.
GriffinC, ShardaN, SoodD, NairJJ, McNultyJ, PandeyS. (2007) Selective cytotoxicity of pancratistatin-related natural Amaryllidaceae alkaloids: evaluation of the activity of two new compounds. Cancer Cell International, 7, 10–16
110.
McNultyJ, NairJJ, BastidaJ, PandeyS, GriffinC. (2009) Structure activity studies on the crinane alkaloid apoptosis-inducing pharmacophore. Natural Product Communications, 4, 483–488
111.
SimpsonCD, AnyiweK, SchimmerAD. (2008) Anoikis resistance and tumor metastasis. Cancer Letters, 272, 177–185
112.
Van GoietsenovenG, AndolfiA, LallemandB, CimminoA, Lamoral-TheysD, GrasT, Abou-DoniaA, DuboisJ, LefrancF, MathieuV, KornienkoA, KissR, EvidenteA. (2010) Amaryllidaceae alkaloids belonging to different structural subgroups display activity against apoptosis-resistant cancer cells. Journal of Natural Products, 73, 1223–1227
NairJJ, RárováL, StrnadM, BastidaJ, Van StadenJ. (2013) Alkaloids from Boophone haemanthoides (Amaryllidaceae). Natural Product Communications, 8, 1705–1710
116.
NairJJ, RárováL, StrnadM, BastidaJ, Van StadenJ. (2014) Crinane alkaloids of the Amaryllidaceae with cytotoxic effects in human cervical adenocarcinoma (HeLa) cells. Natural Product Communications, 9, 461–466
117.
HavelekR, SeifrtovaM, KralovecK, BruckovaL, CahlikovaL, DaleckaM, VavrovaJ, RezacovaM, OpletalL, BilkovaZ. (2014) The effect of Amaryllidaceae alkaloids haemanthamine and haemanthidine on cell cycle progression and apoptosis in p53-negative human leukemic Jurkat cells. Phytomedicine, 21, 479–490.
118.
ÇitoğluGS, AcikaraÖB, YilmazBS, ÖzbekH. (2012) Evaluation of analgesic, anti-inflammatory and hepatoprotective effects of lycorine from Sternbergia fisheriana (Herbert) Rupr. Fitoterapia, 83, 81–87
119.
MaTC, LangleyB, KoB, WeiN, GazaryanIG, ZareenN, YamashiroDJ, WillsDE, RatanRR. (2013) A screen for inducers of p21waf1/cip1 identifies HIF prolyl hydroxylase inhibitors as neuroprotective agents with antitumor properties. Neurobiology of Disease, 49, 13–21
120.
JinA, LiX, ZhuY-Y, YuH-Y, PiH-F, ZhangP, RuanH-L. (2014) Four new compounds from the bulbs of Lycoris aurea with neuroprotective effects against CoCl2 and H2O2-induced SH-SY5Y cell injuries. Archives of Pharmacal Research, 37, 315–323.
121.
StockAM, TroostG, NiggemannB, ZänkerKS, EntschladenF. (2013) Targets for anti-metastatic drug development. Current Pharmaceutical Design, 19, 5127–5134
122.
WongMS, SidikSM, MahmudR, StanslasJ. (2013) Molecular targets in the discovery and development of novel anti-metastatic agents: current progress and future prospects. Clinical and Experimental Pharmacology and Physiology, 40, 307–319
123.
LosM, RoodhartJML, VoestEE. (2007) Target practice: lessons from phase III trials with Bevacizumab and Vatalanib in the treatment of advanced colorectal cancer. The Oncologist, 12, 443–450
